Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 601 to 650 of 756

TitleReference numberPublishedLast updated
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanomaTA321
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosisTA320
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimenTA316
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromesTA317
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanomaTA319
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failureTA314
Canagliflozin in combination therapy for treating type 2 diabetesTA315
Teriflunomide for treating relapsing–remitting multiple sclerosisTA303
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantationTA311
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitisTA308
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hipTA304
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusionTA305
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphomaTA306
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young peopleTA300
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)TA302
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis CTA106
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis CTA75
Pazopanib for the first-line treatment of advanced renal cell carcinomaTA215
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorderTA292
Aflibercept solution for injection for treating wet age‑related macular degenerationTA294
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolismTA287
Mirabegron for treating symptoms of overactive bladderTA290
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancerTA284
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancerTA285
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)TA286
Omalizumab for treating severe persistent allergic asthmaTA278
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fracturesTA279
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosisTA276
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)TA277
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tractTA272
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)TA273
Ipilimumab for previously treated advanced (unresectable or metastatic) melanomaTA268
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)TA270
Dronedarone for the treatment of non-permanent atrial fibrillationTA197
Mannitol dry powder for inhalation for treating cystic fibrosisTA266
Ivabradine for treating chronic heart failureTA267
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumoursTA265
Alteplase for treating acute ischaemic strokeTA264
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolismTA261
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2TA257
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancerTA258
Botulinum toxin type A for the prevention of headaches in adults with chronic migraineTA260
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosisTA254
Pharmalgen for the treatment of bee and wasp venom allergyTA246

Results per page

  1. 10
  2. 25
  3. 50
  4. All